The Role of Pharmacotherapy in Treatment of Meningioma: A Systematic Review

The safety and efficacy of various pharmacotherapeutic regimens on refractory meningiomas have been the focus of investigations. We present a comprehensive review of the previous efforts and the current state of ongoing clinical trials. A PRISMA-compliant review of the MEDLINE and ClinicalTrial.gov...

Full description

Saved in:
Bibliographic Details
Published in:Cancers 2023-01, Vol.15 (2), p.483
Main Authors: Shahbandi, Ataollah, Shah, Darsh S, Hadley, Caroline C, Patel, Akash J
Format: Article
Language:English
Subjects:
Adverse events
Chemotherapy
Clinical trials
Drug therapy
Hematological diseases
Intervention
Medical prognosis
Meningioma
Radiation therapy
Surgery
Survival
Systematic Review
Tumors
Variables
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The safety and efficacy of various pharmacotherapeutic regimens on refractory meningiomas have been the focus of investigations. We present a comprehensive review of the previous efforts and the current state of ongoing clinical trials. A PRISMA-compliant review of the MEDLINE and ClinicalTrial.gov databases of the National Library of Medicine were performed. The primary outcomes of interest for included articles were radiographic response, overall survival, progression-free survival, six-month progression-free survival, and adverse events. Overall, 34 completed trials and 27 ongoing clinical trials were eligible. Six-month progression-free survival was reported in 6-100% of patients in the completed studies. Hematological disorders were the most common adverse events. Of the ongoing clinical trials identified, nine studies are phase I clinical trials, eleven are phase II trials, two are phase I and II trials, one is phase II and III, and two trials do not have a designated phase. Currently, there is no effective chemotherapy for refractory or recurrent meningiomas. Several promising targeted agents have been developed and are currently being investigated in the hope of identifying novel therapeutic strategies for the treatment of this pathology.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers15020483